This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
INCY Stock Down on Disappointing Skin Disease Study Data
by Zacks Equity Research
Incyte declines as data from phase III studies on povorcitinib, for the treatment of hidradenitis suppurativa, fail to meet investor expectations.
BMRN vs. CSLLY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
BMRN vs. CSLLY: Which Stock Is the Better Value Option?
AZN's Imfinzi Gets EU Nod for Limited-Stage Small-Cell Lung Cancer
by Zacks Equity Research
The European Commission approves AstraZeneca's Imfinzi for treating patients with limited-stage small-cell lung cancer based on ADRIATIC study data.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
AZN to Acquire EsoBiotec for $1B to Develop In Vivo Cell Therapies
by Zacks Equity Research
AstraZeneca is set to acquire EsoBiotec for $1 billion to develop in vivo cell therapies for multiple cancer indications or immune-mediated diseases.
AMRN's Q4 Earnings Lag Estimates, Stock Down on Ratio Change Plan
by Zacks Equity Research
Amarin incurs a wider-than-expected loss in Q4. Revenues beat estimates. It plans to initiate a ratio change on its American Depositary Shares. Stock falls.
Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
BioMarin (BMRN) could produce exceptional returns because of its solid growth attributes.
SpringWorks Shares Rise More Than 30% in 3 Months: Here's Why
by Zacks Equity Research
SWTX's desmoid tumor drug, Ogsiveo, is driving its top line. The recent FDA nod for Gomekli to treat a rare tumor diversifies its commercial portfolio.
Wall Street Analysts Believe BioMarin (BMRN) Could Rally 36.57%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 36.6% upside potential for BioMarin (BMRN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Buy These 5 Top-Ranked Stocks to Play Likely Earnings Beat
by Sanghamitra Saha
Top-ranked stocks Doximity (DOCS), Life Time Group Holdings (LTH), Adtalem Global Education (ATGE), BioMarin Pharmaceutical (BMRN) and Iridium Communications (IRDM) are likely to beat on the bottom line in their upcoming releases.
NVO Stock Down 9% as CagriSema Misses Target in Second Obesity Study
by Zacks Equity Research
Novo Nordisk stock slumps as the 15.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in the second phase III study, missing the guidance of 25%.
PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study
by Zacks Equity Research
The phase IIb ANTHEM-UC study evaluating Protagonist and JNJ's icotrokinra for treating ulcerative colitis meets the primary endpoint.
BEAM Down Despite Positive Initial Data From Genetic Disorder Study
by Zacks Equity Research
Beam Therapeutics posts positive initial data from a phase I/II study investigating BEAM-302 for treating alpha-1 antitrypsin deficiency.
KOD Completes Enrollment in Phase III Study for Eye Disease Candidate
by Zacks Equity Research
Kodiak reports completing patient enrollment in its late-stage study evaluating tarcocimab for diabetic retinopathy.
Teladoc Boosts Weight Care Access With LillyDirect, Aids Growth
by Zacks Equity Research
TDOC expands weight care access with LillyDirect, boosting growth by offering affordable GLP-1 medications like Zepbound, enhancing patient outcomes and engagement.
INCY Opzelura Shows Superior Efficacy in 2 Prurigo Nodularis Studies
by Zacks Equity Research
Incyte reports positive data from two phase III studies evaluating Opzelura for prurigo nodularis in adults.
EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCC
by Zacks Equity Research
The EC approves BMY's combination of Opdivo and Yervoy for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma.
LLY/INCY Olumiant Shows Superior Efficacy in Pediatric Alopecia Study
by Zacks Equity Research
Eli Lilly and INCY announce positive efficacy data from the late-stage alopecia study of baricitinib in adolescent patients.
4 Discounted PEG Stocks Offering the Best Returns to Value Investors
by Urmimala Biswas
Here we present four discounted PEG stocks that qualify our screening criteria, TAP, BMRN, DVN and JAZZ.
Krystal Biotech Rises 15.8% in a Month: Should You Buy Now or Wait?
by Zacks Equity Research
KRYS stock surges 15% in a month on strong uptake of Vyjuvek and encouraging pipeline progress. We are optimistic about the stock as we believe there is room for further growth.
PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy
by Zacks Equity Research
The FDA bestows an Orphan Drug tag to Plus Therapeutics' investigational drug, rhenium (186Re) obisbemeda, for treating leptomeningeal metastases in lung cancer patients.
Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
by Zacks Equity Research
EDIT stock is down following the announcement of dismal fourth-quarter 2024 results as both earnings and revenues miss estimates.
FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus
by Zacks Equity Research
FATE Therapeutics' Q4 loss and revenues improve year over year. Its innovative pipeline is in focus.